Background
The most common vaccine trial design is performed in the same manner as a drug trial. However, it is now understood that important differences in the causal models underlying trials of drugs to cure non-infectious diseases, and vaccines to prevent infectious diseases, cause the drug trial designs to be inadequate for vaccines. This has motivated the development of several new approaches to vaccine trial design [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . This paper describes a new design appropriate for HIV vaccine trials called the Retrospective Partner Trial (RPT) design and illustrates the usefulness of simulations in comparing the power of different trial designs.
To understand how different vaccine trial designs measure different vaccine effects, consider the standard drug trial designs which have commonly been used for vaccine trials [11] [12] [13] [14] [15] [16] [17] . In [1] [2] [3] [4] [5] [6] [7] [8] lack the statistical power to detect those effects when a small number of trial subjects become infected. The RPT design was developed in an attempt to increase statistical power under these circumstances.
There have been several trial designs proposed recently, including those that use partnership information [18] . The RPT [19, 20] Figure 1 contributes a count of three partnerships to the denominator of the SAR (partnerships A, D and E were in existence after the end of partnership C, which was the first partnership to end with a genetically related HIV sequence) and one partnership to the numerator (partnership A was in existence after partnership C ended and thus it is presumed that the trial subject case infected partner A).
Potential biases or loss of precision could result from the inability of classification rules to accurately time the infectiousness of the trial subject case. For example, consider the two hypothetical infection times which are marked with dots in Figure 1 [39, 40] , sexual role preferences [41, 42] , concurrent partnership potential [43, 44] , and rates of sexual activity [45, 46] . It [37] .
Vaccination
The simulation model provides a mechanism by which both the contagiousness and susceptibility effects of a vaccine can independently influence HIV transmission probabilities in order to allow assessments of vaccine efficacy statistics. This mechanism functions as follows. When calculating the transmission probability during a sexual contact as is described in Section 4.3, if the infected partner has been vaccinated, then the probability is multiplied by 1-VEI. If the uninfected partner has been vaccinated, then the transmission probability is multiplied by 1-VES . If [51, 52] . In a fraction of the study population, the vaccine has no effect and thus VES = VEI = 0. In the remaining fraction of the study population, VES and VE, are sampled from a Beta distribution. Figure 4 , the null distribution for VES is presented on the same horizontal scale as the distribution of VES when VES was set to .25. As would occur in any real-world vaccine trials, the random events related to partnership formation and HIV transmission cause the realized VES estimates from each simulation to form a distribution of VES estimates centered on the actual vaccine effects possessed by the vaccines. Because of the low VES in this case, the two distributions overlap considerably. The vertical line in Figure 4 indicates the rejection region on the null distribution for an alpha level of .05. The corresponding area to the right of this line on the VES =.25 distribution includes only 11% of the simulated vaccine trials, indicating that the statistical power would be particularly poor under these circumstances. The RPT design would obtain exactly the same estimate for VES as realized by the standard trial design. In 89% of the simulated vaccine trials, both the standard design and the RPT design would have rejected the vaccine due to the poor VES effects of the vaccine.
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In contrast to the standard design, the RPT 
